Indication

For the treatment of moderate-to-severe atopic dermatitis in adult and adolescents 12 years and older who are candidates for systemic therapy

Medicine details

Medicine name:
dupilumab (Dupixent)
SMC ID:
SMC2232
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Skin
Submission type
Abbreviated
Status
Publication due date:
13 January 2020
SMC meeting date:
03 December 2019